Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs The Coca-Cola Co K (KO) Price & Performance

Ginkgo Bioworks Holdings IncTrade
The Coca-Cola Co KTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs The Coca-Cola Co K — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while The Coca-Cola Co K trades at $86.78 (market cap $372.08B). The key difference: The Coca-Cola Co K is far larger — about 735.7× Ginkgo Bioworks Holdings Inc's market cap, and The Coca-Cola Co K pays a 2.45% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAKO
Market Cap
$505.73M$372.08B
Sector
HealthConsumer Staples
52-Week High
$16.14$89.08
52-Week Low
$5.48$65.67
Enterprise Value
$607.68M$399.26B
Volume
14,630,257
Dividend Yield
2.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.67, down 0.23% on the day, with a bullish technical signal driven by moving averages and strong support at $85. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains high profitability margins, including a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends, while the upcoming Q3 2026 earnings are anticipated at $0.87 EPS.

The stock offers a compelling dividend yield with 64 consecutive years of increases, supported by solid cash flow and a consensus price target of $95.83 implying 10.6% upside. Risks include regional demand volatility in Asia and high debt levels, but analyst sentiment is bullish with 60% buy ratings. Long-term growth prospects remain intact given brand strength and global footprint.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO